US20140017200A1 - Modified two-component gelation systems, methods of use and methods of manufacture - Google Patents
Modified two-component gelation systems, methods of use and methods of manufacture Download PDFInfo
- Publication number
- US20140017200A1 US20140017200A1 US13/941,759 US201313941759A US2014017200A1 US 20140017200 A1 US20140017200 A1 US 20140017200A1 US 201313941759 A US201313941759 A US 201313941759A US 2014017200 A1 US2014017200 A1 US 2014017200A1
- Authority
- US
- United States
- Prior art keywords
- functionalized polymer
- polyethylene glycol
- buffer
- terminated polyethylene
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Ischemic heart disease typically results from an imbalance between the myocardial blood flow and the metabolic demand of the myocardium. Progressive atherosclerosis with increasing occlusion of coronary arteries leads to a reduction in coronary blood flow, which creates ischemic heart tissue.
- Atherosclerosis is a type of arteriosclerosis in which cells including smooth muscle cells and macrophages, fatty substances, cholesterol, cellular waste product, calcium and fibrin build up in the inner lining of a body vessel.
- Arteriosclerosis refers to the thickening and hardening of arteries. Blood flow can be further decreased by additional events such as changes in circulation that lead to hypoperfusion, vasospasm or thrombosis.
- MI Myocardial infarction
- an MI was caused from a slow progression of closure from, for example, 95% then to 100%.
- an MI can also be a result of minor blockages where, for example, there is a rupture of the cholesterol plaque resulting in blood clotting within the artery.
- This damage can cause irregular rhythms that can be fatal, even though the remaining muscle is strong enough to pump a sufficient amount of blood.
- scar tissue tends to naturally form.
- a mechanical procedure includes balloon angioplasty with stenting
- a therapeutic agent application includes administering a thrombolytic agent, such as urokinase.
- a thrombolytic agent such as urokinase.
- Such procedures do not, however, treat actual tissue damage to the heart.
- Other systemic drugs such as ACE-inhibitors and Beta-blockers, may be effective in reducing cardiac load post-MI, although a significant portion of the population that experiences a major MI ultimately develop heart failure.
- An important component in the progression to heart failure is remodeling of the heart due to mismatched mechanical forces between the infarcted region and the healthy tissue resulting in uneven stress and strain distribution in the left ventricle.
- remodeling of the heart begins.
- the principle components of the remodeling event include myocyte death, edema and inflammation, followed by fibroblast infiltration and collagen deposition, and finally scar formation from extra-cellular matrix (ECM) deposition.
- ECM extra-cellular matrix
- the principle component of the scar is collagen which is non-contractile and causes strain on the heart with each beat. Non-contractility causes poor pump performance as seen by low ejection fraction (EF) and akinetic or diskinetic local wall motion.
- compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed.
- the composition includes at least two components.
- a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5.
- a second component can include a second buffer in a pH of between about 7.5 and 9.0.
- a second functionalized polymer can be included in the first or second component.
- the composition can include at least one cell type and/or at least one growth factor.
- the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
- FIGS. 1A-1B illustrate the progression of heart damage once the build-up of plaque in an artery induces an infarct to occur.
- FIGS. 2A-2G show examples of chemical structures of a functionalized polyethylene glycol.
- FIG. 3 shows a general formula for the chemical structure of a functionalized polyethylene glycol.
- FIG. 4 illustrates an embodiment of a dual bore delivery device.
- FIGS. 5A-5B illustrate an alternative embodiment of a dual bore delivery device.
- FIGS. 6A-6C illustrate a second alternative embodiment of a dual bore delivery device.
- FIGS. 1A-1B illustrate the progression of heart damage once the build-up of plaque induces an infarct to occur.
- FIG. 1A illustrates a site 10 where blockage and restricted blood flow can occur from, for example, a thrombus or embolus.
- FIG. 1B illustrates resultant damage area 20 to the left ventricle that can result from the lack of oxygen and nutrient flow carried by the blood to the inferior region left of the heart. Damage area 20 will likely undergo remodeling, and eventually scarring, resulting in a non-functional area.
- Bioscaffoldings formed of two components and applied in situ to the left heart ventricle can be used to treat post-myocardial infarction tissue damage.
- Bioscaffolding” and “two-component gelation system” and “gelation system” are hereinafter used interchangeably.
- two-component gelation systems include, but are not limited to, alginate construct systems, fibrin glues and fibrin glue-like systems, self-assembled peptides, synthetic polymer systems and combinations thereof.
- Each component of the two-component gelation system may be co-injected to an infarct region by a dual-lumen delivery device.
- dual-lumen delivery devices include, but are not limited to, dual-needle left-ventricle injection devices, dual-needle transvascular wall injection devices and the like.
- the two-component gelation system includes fibrin glue.
- Fibrin glue consists of two main components, fibrinogen and thrombin.
- Fibrinogen is a plasma glycoprotein of about 340 kiloDaltons (kDa) in its endogenous state.
- Fibrinogen is a symmetrical dimer comprised of six paired polypeptide chains, alpha, beta and gamma chains. On the alpha and beta chains, there is a small peptide sequence called a fibrinopeptide which prevents fibrinogen from spontaneously forming polymers with itself.
- fibrinogen is modified with proteins.
- Thrombin is a coagulation protein.
- thrombin When combined in equal volumes, thrombin converts the fibrinogen to fibrin by enzymatic action at a rate determined by the concentration of thrombin. The result is a biocompatible gel which gelates when combined at the infarct region.
- Fibrin glue can undergo gelation between about 5 to about 60 seconds.
- fibrin glue-like systems include, but are not limited to, TisseelTM (Baxter), Beriplast PTM (Aventis Behring), Biocol® (LFB, France), CrossealTM (Omrix Biopharmaceuticals, Ltd.), Hemaseel HMN® (Haemacure Corp.), Bolheal (Kaketsuken Pharma, Japan) and CoStasis® (Angiotech Pharmaceuticals).
- the two-component gelation system includes self-assembled peptides.
- Self-assembled peptides generally include repeat sequences of alternating hydrophobic and hydrophilic amino acid chains.
- the hydrophilic amino acids are generally charge-bearing and can be anionic, cationic or both.
- Examples of cationic amino acids are lysine and arginine.
- Examples of anionic amino acids are aspartic acid and glutamic acid.
- hydrophobic amino acids are alanine, valine, leucine, isoleucine or phenylalanine.
- Self-assembled peptides can range from 8 to 40 amino acids in length and can assemble into nanoscale fibers under conditions of physiological pH and osmolarity.
- self-assembled peptides typically undergo gelation between several minutes to several hours.
- self-assembled peptides include, but are not limited to: AcN-RARADADARARADADA-CNH 2 (RAD 16-II) wherein R is arginine, A is alanine, D is aspartic acid, and Ac indicates acetylation; VKVKVKVKV-PP-TKVKVKVKV-NH 2 (MAX-1) wherein V is valine, K is lysine and P is proline; and AcN-AEAEAKAKAEAEAKAK-CNH 2 wherein A is alanine, K is lysine and E is glutamic acid (EAK16-II).
- the two-component gelation system is an alginate construct system.
- One component may be an alginate conjugate (or alginate alone) which can include alginate and a protein constituent.
- the second component may be a salt.
- alginate conjugates can include, but are not limited to, alginate-collagen, alginate-laminin, alginate-elastin, alginate-collagen-laminin and alginate-hyaluronic acid in which the collagen, laminin, elastin, collagen-laminin or hyaluronic acid is covalently bonded (or not bonded) to alginate.
- salts which can be used to gel the alginate constructs include, but are not limited to, calcium chloride (CaCl 2 ), barium chloride (BaCl 2 ) or strontium chloride (SrCl 2 ).
- the alginate construct is alginate-gelatin.
- the molecular weight of the gelatin may be in the approximate range of 5 kDa to 100 kDa.
- the relatively low molecular weight of gelatin offers processing advantages in that it is more soluble and has lower viscosity than hydrogels of higher molecular weight.
- Another advantage of gelatin is that it contains from 1 to 4 RGD (arginine-glycine-aspartic acid peptide sequence) sites per molecule.
- RGD is a common cell adhesion ligand and would increase the retention of cells within the infarct zone where the bioscaffolding is formed.
- the cells retained by the RGD sites may be cells co-injected with the bioscaffolding components or dispersed throughout a component of the system.
- the gelatin may be a porcine gelatin or a recombinant human gelatin.
- the porcine gelatin is a hydrolyzed type 1 collagen extracted from porcine skin.
- the molecular weight of the porcine gelatin is approximately 20 kDa.
- the human gelatin is produced by bacteria using human genetic material.
- the human recombinant gelatin is equivalent to the porcine gelatin but may reduce the likelihood of an immune response when injected into an infarct region of a human subject.
- Alginate is a linear polysaccharide derived from seaweed and contains mannuronic (M) and guluronic acid (G), presented in both alternating blocks and alternating individual residues. It is possible to use some of the carboxyl groups of the alginate as sites to graft useful cell adhesion ligands, such as collagen, laminin, elastin and other peptide fragments of the ECM matrix, forming an alginate conjugate, because alginate does not have RGD groups for cell attachment.
- M mannuronic
- G guluronic acid
- the alginate-gelatin conjugate can be formed of approximately 1% to 30% and more particularly approximately 10% to 20% gelatin (either porcine or human recombinant) and approximately 80% to 90% alginate.
- gelatin either porcine or human recombinant
- a relatively lower proportion of gelatin is used in the conjugate to retain gelation capacity of native alginate because the carboxyl groups of alginate that cause the gelation may be bound up in the alginate-gelatin conjugate.
- the two-component gelation system includes polyethylene glycols.
- PEG is a synthetic polymer having the repeating structure (OCH 2 CH 2 ) n .
- a first component may be a polyethylene glycol (PEG) polymer functionalized with at least two nucleophilic groups. Examples of nucleophilic groups include, but are not limited to, thiol (—SH), thiol anion (—S ⁇ ), and amine (—NH 2 ).
- a “nucleophile” is a reagent which is attracted to centers of positive charge. A nucleophile participates in a chemical reaction by donating electrons to an electrophile in order to form a chemical bond.
- a second component may be a PEG polymer functionalized with at least two electrophilic groups.
- electrophilic groups include, but are not limited to, N-hydroxy succinimide ester (—NHS), acrylate, vinyl sulfone, and maleimide.
- —NHS, or succinimidyl is a five-member ring structure represented by the chemical formula —N(COCH 2 ) 2 .
- An “electrophile” is a reagent attracted to electrons that participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile. The total number of electrophilic and nucleophilic groups should be greater than 4.
- two functionalized PEGs comprising a PEG functionalized with at least two nucleophilic groups and a PEG functionalized with at least two electrophilic groups can be combined in a 1:1 ratio.
- the PEGs can be stored in a 0.01M acidic solution at a pH below about 4.0. At room temperature and standard concentration, reaction and cross-linking between the two functionalized PEGs occurs beginning at approximately pH greater than 6.5. Under these conditions, reaction kinetics are slow. When 0.3 M basic buffer solution at pH about 9.0 is added to the PEGs, gelation occurs in less than 1 minute. This system exhibits poor cytocompatibility due to the low pH of the functionalized PEG solution and the high osmolality pH 9.0 buffer. “Cytocompatibility” refers to the ability of media to provide an environment conducive to cell growth. Additionally, this system does not include any cell adhesion sites.
- a bioscaffolding is formed from combining functionalized polymers (bioscaffolding precursors) with an extra-cellular matrix (ECM) protein at physiological osmolality.
- the resulting bioscaffolding can be in a pH range of between about 6.5 and about 7.5.
- ECM proteins include, but are not limited to, collagen, laminin, elastin and fragments thereof, in addition to, proteins, protein fragments and peptides with cell adhesion ligands such as RGD groups.
- cells can be added to the bioscaffolding precursors.
- Examples of cell types include, but are not limited to, localized cardiac progenitor cells, mesenchymal stem cells (osteoblasts, chondrocytes and fibroblasts), bone marrow derived mononuclear cells, adipose tissue derived stem cells, embryonic stem cells, umbilical-cord-blood-derived stem cells, smooth muscle cells or skeletal myoblasts.
- growth factors can be added to the system. Examples of growth factors include, but are not limited to, isoforms of vasoendothelial growth factor (VEGF), fibroblast growth factor (FGF, e.g.
- VEGF vasoendothelial growth factor
- FGF fibroblast growth factor
- beta-FGF Del 1, hypoxia inducing factor (HIF 1-alpha), monocyte chemoattractant protein (MCP-1), nicotine, platelet derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), transforming growth factor (TGF alpha), hepatocyte growth factor (HGF), estrogens, follistatin, proliferin, prostaglandin E1 and E2, tumor necrosis factor (TNF-alpha), interleukin 8 (Il-8), hematopoietic growth factors, erythropoietin, granulocyte-colony stimulating factors (G-CSF) and platelet-derived endothelial growth factor (PD-ECGF).
- the polymers can include synthetic polymers, such as polyamino acids, polysaccharides, polyalkylene oxide or polyethylene glycol (PEG).
- the molecular weight of the compounds can vary depending on the desired application. In most instances, the molecular weight (mol. wt.) is about 100 to about 100,000 mol. wt., and more preferably about 1,000 to about 20,000 mol. wt.
- the polymer is polyethylene glycol.
- polyethylene glycol(s) includes modified and/or derivatized polyethylene glycols.
- a first functionalized PEG can be functionalized by at least two reactive groups, such as electrophilic groups. Examples of reactive groups include, but are not limited to, a succinimidyl group (—NHS), a vinyl group, such as acrylate, vinylsulfone, vinyl ether, allyl ether, vinyl ester, vinyl ketone or maleimide, and nitrophenolate or similar leaving group.
- a second functionalized PEG can be functionalized by at least two reactive groups, such as nucleophilic groups.
- Examples of reactive groups include, but are not limited to, a thiol group, an amino group, a hydroxyl group, phosphine radical (PH 2 ) and —CO—NH—NH 2 .
- Representative functionalized PEGs with electrophilic groups are shown in FIGS. 2A through 2G .
- a general representative formula for functionalized PEGs with nucleophilic groups are shown in FIG. 3 .
- a PEG functionalized with electrophilic groups is combined with a PEG functionalized with nucleophilic groups to form a bioscaffolding gel. The total number of electrophilic and nucleophilic groups should be greater than 4.
- the branched conformation of the PEGs represented in FIGS. 2A-2G & 3 is not limiting.
- the combined functionality of the PEGs can be greater than four.
- “Functionality” refers to the number of electrophilic or nucleophilic groups on the polymer core that are capable of reacting with other nucleophilic or electrophilic groups, respectively, to form a gel. That is, as long as the PEGs to be combined are at least difunctional, i.e., each PEG contains at least two nucleophilic or electrophilic groups, the functionalized PEGs can be combined to form a bioscaffolding gel. The total number of electrophilic and nucleophilic groups should therefore be greater than 4.
- a bioscaffolding can include a first component with at least one functionalized PEG and an ECM protein, and a second component of buffer.
- “Component” hereinafter refers to one part of a two-part system and can include multiple constituents (e.g., a mixture).
- the first component can include a mixture of a first functionalized PEG, such as —NHS PEG (or other functionalized PEG with at least two reactive groups), a second functionalized PEG, such as —SH PEG (or other functionalized PEG with at least two reactive groups), and an ECM protein.
- the first component can include first functionalized polymer only, such as —NHS PEG (or other functionalized PEG with at least two reactive groups) and an ECM protein.
- the first functionalized PEG can be combined with the second functionalized PEG in a 1:1 ratio.
- the functionalized PEGs can be combined in a ratio less than 1:1.
- the two PEGs can have different number of functional groups and, as a result, the PEG stoichiometry could be altered.
- the crosslinking density may be altered by varying the polymer ratio.
- the functionalized PEGs are combined in the solid phase.
- the mixture can be suspended in a pH 6.5 buffer at approximately physiological osmolality, i.e., 280-300 mOsm/kg H 2 O.
- buffers include, but are not limited to dilute hydrogen chloride and citrate buffers.
- the second component can include a buffer in a pH range from approximately 7.5 to 9.5 at a concentration from about 140 mM to about 150 mM.
- buffers include sodium phosphate and sodium carbonate buffers.
- the buffer can be at approximately physiological osmolality, i.e., 280-300 mOsm/kg H 2 O.
- the second component can include an —SH PEG and the buffer (or other functionalized PEG with at least two reactive groups).
- a cell type can be added to the first component.
- cell types include, but are not limited to, localized cardiac progenitor cells, mesenchymal stem cells (osteoblasts, chondrocytes and fibroblasts), bone marrow derived mononuclear cells, adipose tissue derived stem cells, embryonic stem cells, umbilical-cord-blood-derived stem cells, smooth muscle cells or skeletal myoblasts.
- hMSC human mesenchymal stem cells
- a growth factor can be added to the first component.
- the functionalized PEGs can react with the growth factors which could stabilize the growth factors, extend their half-life or provide a mode for controlled release of the growth factors.
- the growth factors can act to help survival of injected hMSC or endogenous progenitor cells at the infarct region.
- the growth factors can aid direct endogenous progenitor cells to the injury site.
- cells do not attach to PEG surfaces or gels formed from PEG polymers. That is, PEG polymers do not provide a cytocompatible environment for cells.
- Collagen or gelatin or any other ECM protein such as fibronectin, may be added to improve cytocompatibility.
- the collagen added to the mixture of PEGs can make the mixture very viscous and therefore not conducive with catheter delivery systems. It is anticipated that the pH of the first component and the concentration of the second component, as described in embodiments of the invention, will increase the cytocompatibility of the cell types even with an ECM protein present.
- the first component can be combined with the second component to produce a bioscaffolding at an infarct region.
- the resulting bioscaffolding gel can be at a pH of between 6.8 and 7.4.
- the low buffer concentration of the second component may slow the reaction down, the resulting gel can enable improved cytocompatibility.
- the ECM protein can provide cell adhesion cites to enable cell spreading and migration. “Cell spreading” refers to the naturally occurring morphology that some cells attain when they are allowed to grow on cytocompatible surfaces. In the case of hMSC, the natural morphology is a flattened, spindle-shaped morphology.
- the N-terminus and lysine and arginine side groups of the ECM may react with the —NHS PEG. This may provide better mechanical stability of the gel and reduce the tendency of the gel to swell. This reaction is what forms the gel.
- the —NHS group of the —NHS PEG can be replaced with a vinyl constituent such as acrylate, vinylsulfone, vinyl ketone, allyl ester, allyl ketone or maleimide group(s).
- a vinyl constituent such as acrylate, vinylsulfone, vinyl ketone, allyl ester, allyl ketone or maleimide group(s).
- Michael type reactions are well known by those skilled in the art.
- the reaction could be activated with a buffer in a pH range of between about 6.0 and about 9.0, by a catalytic amount of various amines or a combination thereof.
- the —NHS group of the —NHS PEG can be replaced with a leaving group such as a nitrophenolate.
- the —SH group of the —SH PEG can be replaced with an amino group to form an amide bond when combined with an —NHS or alternatively functionalized PEG.
- Devices which can be used to deliver each component of the gel include, but are not limited to, dual-needle left-ventricle injection devices, dual-needle transvascular wall injection and dual syringes.
- Methods of access to use the minimally invasive (i.e., percutaneous or endoscopic) injection devices include access via the femoral artery or the sub-xiphoid.
- Xiphoid or “xiphoid process” is a pointed cartilage attached to the lower end of the breastbone or sternum, the smallest and lowest division of the sternum. Both methods are known by those skilled in the art.
- FIG. 4 illustrates an embodiment of a dual syringe device which can be used to deliver the compositions of the present invention.
- Dual syringe 400 can include first barrel 410 and second barrel 420 adjacent to one another and connected at a proximal end 455 , distal end 460 and middle region 465 by plates 440 , 445 and 450 , respectively.
- barrels 410 and 420 can be connected by less than three plates.
- Each barrel 410 and 420 includes plunger 415 and plunger 425 , respectively.
- Barrels 410 and 420 can terminate at a distal end into needles 430 and 435 , respectively, for extruding a substance.
- barrels 410 and 420 can terminate into cannula protrusions for extruding a substance. Barrels 410 and 420 should be in close enough proximity to each other such that the substances in each respective barrel are capable of mixing with one another to form a bioscaffolding in the treatment area, e.g., a post-infarct myocardial region.
- Dual syringe 400 can be constructed of any metal or plastic which is minimally reactive or completely unreactive with the formulations described in the present invention. In some embodiments, dual syringe 400 includes a pre-mixing chamber attached to distal end 465 .
- first barrel 410 can include a first component of a two-component polyethylene glycol gelation system and second barrel 420 can include a second component of the system according to any of the embodiments described previously.
- a therapeutic amount of the resulting gel is between about 25 ⁇ L to about 200 ⁇ L, preferably about 50 ⁇ L.
- Dual syringe 400 can be used during, for example, an open chest surgical procedure.
- FIGS. 5A-5B illustrate an embodiment of a dual-needle injection device which can be used to deliver the compositions of the present invention.
- Delivery assembly 500 includes lumen 510 which may house delivery lumens, guidewire lumens and/or other lumens. Lumen 510 , in this example, extends between distal portion 505 and proximal end 515 of delivery assembly 500 .
- delivery assembly 500 includes first needle 520 movably disposed within delivery lumen 530 .
- Delivery lumen 530 is, for example, a polymer tubing of a suitable material (e.g., polyamides, polyolefins, polyurethanes, etc.).
- First needle 520 is, for example, a stainless steel hypotube that extends a length of the delivery assembly.
- First needle 520 includes a lumen with an inside diameter of, for example, 0.08 inches (0.20 centimeters).
- first needle 520 has a needle length on the order of about 40 inches (about 1.6 meters) from distal portion 505 to proximal portion 515 .
- Lumen 510 also includes auxiliary lumen 540 extending, in this example, co-linearly along the length of the catheter (from a distal portion 505 to proximal portion 515 ).
- Auxiliary lumen 540 is, for example, a polymer tubing of a suitable material (e.g., polyamides, polyolefins, polyurethanes, etc.).
- auxiliary lumen 540 is terminated at a delivery end of second needle 550 and co-linearly aligned with a delivery end of needle 520 .
- Auxiliary lumen 540 may be terminated to a delivery end of second needle 550 with a radiation-curable adhesive, such as an ultraviolet curable adhesive.
- Second needle 550 is, for example, a stainless steel hypotube that is joined co-linearly to the end of main needle 520 by, for example, solder (illustrated as joint 555 ). Second needle 550 has a length on the order of about 0.08 inches (0.20 centimeters).
- FIG. 5B shows a cross-sectional front view through line A-A′ of delivery assembly 500 .
- FIG. 5B shows main needle 520 and second needle 550 in a co-linear alignment.
- auxiliary lumen 540 is terminated to auxiliary side arm 460 .
- Auxiliary side arm 560 includes a portion extending co-linearly with main needle 520 .
- Auxiliary side arm 560 is, for example, a stainless steel hypotube material that may be soldered to main needle 520 (illustrated as joint 565 ).
- Auxiliary side arm 560 has a co-linear length on the order of about, in one example, 1.2 inches (3 centimeters).
- the proximal end of main needle 520 includes adaptor 570 for accommodating a substance delivery device (e.g., a component of a two-component bioerodable gel material).
- Adaptor 570 is, for example, a molded female luer housing.
- a proximal end of auxiliary side arm 560 includes adaptor 580 to accommodate a substance delivery device (e.g., a female luer housing).
- a gel may be formed by a combination (mixing, contact, etc.) of a first component and a second component.
- a first component may be introduced by a one cubic centimeters syringe at adaptor 570 through main needle 520 .
- second component including a silk protein and optionally a least one cell type may be introduced with a one cubic centimeter syringe at adaptor 580 .
- FIGS. 6A-6C illustrate an alternative embodiment of a dual-needle injection device which can be used to deliver two-component gel compositions of the present invention.
- the catheter assembly 600 provides a system for delivering substances, such as two-component gel compositions, to or through a desired area of a blood vessel (a physiological lumen) or tissue in order to treat a myocardial infarct region.
- the catheter assembly 600 is similar to the catheter assembly 600 described in commonly-owned, U.S. Pat. No. 6,554,801, titled “Directional Needle Injection Drug Delivery Device”, which is incorporated herein by reference.
- catheter assembly 600 is defined by elongated catheter body 650 having proximal portion 620 and distal portion 610 .
- Guidewire cannula 670 is formed within catheter body (from proximal portion 610 to distal portion 620 ) for allowing catheter assembly 600 to be fed and maneuvered over guidewire 680 .
- Balloon 630 is incorporated at distal portion 610 of catheter assembly 600 and is in fluid communication with inflation cannula 660 of catheter assembly 600 .
- Balloon 630 can be formed from balloon wall or membrane 635 which is selectively inflatable to dilate from a collapsed configuration to a desired and controlled expanded configuration. Balloon 630 can be selectively dilated (inflated) by supplying a fluid into inflation cannula 660 at a predetermined rate of pressure through inflation port 665 (located at proximal end 620 ). Balloon wall 635 is selectively deflatable, after inflation, to return to the collapsed configuration or a deflated profile. Balloon 630 may be dilated (inflated) by the introduction of a liquid into inflation cannula 660 . Liquids containing treatment and/or diagnostic agents may also be used to inflate balloon 630 .
- balloon 630 may be made of a material that is permeable to such treatment and/or diagnostic liquids.
- the fluid can be supplied into inflation cannula 660 at a predetermined pressure, for example, between about one and 20 atmospheres.
- the specific pressure depends on various factors, such as the thickness of balloon wall 635 , the material from which balloon wall 635 is made, the type of substance employed and the flow-rate that is desired.
- Catheter assembly 600 also includes at least two substance delivery assemblies 605 a and 605 b (not shown; see FIGS. 6B-6C ) for injecting a substance into a myocardial infarct region.
- substance delivery assembly 605 a includes needle 615 a movably disposed within hollow delivery lumen 625 a .
- Delivery assembly 605 b includes needle 615 b movably disposed within hollow delivery lumen 625 b (not shown; see FIGS. 6B-6C ). Delivery lumen 625 a and delivery lumen 625 b each extend between distal portion 610 and proximal portion 620 .
- Delivery lumen 625 a and delivery lumen 625 b can be made from any suitable material, such as polymers and copolymers of polyamides, polyolefins, polyurethanes and the like. Access to the proximal end of delivery lumen 625 a or delivery lumen 625 b for insertion of needle 615 a or 615 b , respectively is provided through hub 635 (located at proximal end 620 ). Delivery lumens 625 a and 625 b may be used to deliver first and second components of a two-component gel composition to a post-myocardial infarct region.
- FIG. 6B shows a cross-section of catheter assembly 600 through line A-A′ of FIG. 6A (at distal portion 610 ).
- FIG. 6C shows a cross-section of catheter assembly 600 through line B-B′ of FIG. 6A .
- delivery assemblies 605 a and 605 b are adjacent to each other. The proximity of delivery assemblies 605 a and 605 b allows each component of the two-component gelation system to rapidly gel when delivered to a treatment site, such as a post-myocardial infarct region.
Abstract
Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Description
- The application is a continuation of U.S. patent application Ser. No. 12/756,092, filed Apr. 7, 2010 (issued as U.S. Pat. No. 8,486,386), and U.S. patent application Ser. No. 12/756,119, filed Apr. 7, 2010 (issued as U.S. Pat. No. 8,486,387), which are divisional applications of U.S. patent application Ser. No. 11/496,824, filed Jul. 31, 2006 (issued as U.S. Pat. No. 7,732,190) and incorporated herein by reference.
- Post-myocardial infarction treatments and compositions.
- Ischemic heart disease typically results from an imbalance between the myocardial blood flow and the metabolic demand of the myocardium. Progressive atherosclerosis with increasing occlusion of coronary arteries leads to a reduction in coronary blood flow, which creates ischemic heart tissue. “Atherosclerosis” is a type of arteriosclerosis in which cells including smooth muscle cells and macrophages, fatty substances, cholesterol, cellular waste product, calcium and fibrin build up in the inner lining of a body vessel. “Arteriosclerosis” refers to the thickening and hardening of arteries. Blood flow can be further decreased by additional events such as changes in circulation that lead to hypoperfusion, vasospasm or thrombosis.
- Myocardial infarction (MI) is one form of heart disease that results from the sudden lack of supply of oxygen and other nutrients. The lack of blood supply is a result of a closure of the coronary artery (or any other artery feeding the heart) which nourishes a particular part of the heart muscle. The cause of this event is generally attributed to arteriosclerosis in coronary vessels.
- Formerly, it was believed that an MI was caused from a slow progression of closure from, for example, 95% then to 100%. However, an MI can also be a result of minor blockages where, for example, there is a rupture of the cholesterol plaque resulting in blood clotting within the artery. Thus, the flow of blood is blocked and downstream cellular damage occurs. This damage can cause irregular rhythms that can be fatal, even though the remaining muscle is strong enough to pump a sufficient amount of blood. As a result of this insult to the heart tissue, scar tissue tends to naturally form.
- Various procedures, including mechanical and therapeutic agent application procedures, are known for reopening blocked arties. An example of a mechanical procedure includes balloon angioplasty with stenting, while an example of a therapeutic agent application includes administering a thrombolytic agent, such as urokinase. Such procedures do not, however, treat actual tissue damage to the heart. Other systemic drugs, such as ACE-inhibitors and Beta-blockers, may be effective in reducing cardiac load post-MI, although a significant portion of the population that experiences a major MI ultimately develop heart failure.
- An important component in the progression to heart failure is remodeling of the heart due to mismatched mechanical forces between the infarcted region and the healthy tissue resulting in uneven stress and strain distribution in the left ventricle. Once an MI occurs, remodeling of the heart begins. The principle components of the remodeling event include myocyte death, edema and inflammation, followed by fibroblast infiltration and collagen deposition, and finally scar formation from extra-cellular matrix (ECM) deposition. The principle component of the scar is collagen which is non-contractile and causes strain on the heart with each beat. Non-contractility causes poor pump performance as seen by low ejection fraction (EF) and akinetic or diskinetic local wall motion. Low EF leads to high residual blood volume in the ventricle, causes additional wall stress and leads to eventual infarct expansion via scar stretching and thinning and border-zone cell apoptosis. In addition, the remote-zone thickens as a result of higher stress which impairs systolic pumping while the infarct region experiences significant thinning because mature myocytes of an adult are not regenerated. Myocyte loss is a major etiologic factor of wall thinning and chamber dilation that may ultimately lead to progression of cardiac myopathy. In other areas, remote regions experience hypertrophy (thickening) resulting in an overall enlargement of the left ventricle. This is the end result of the remodeling cascade. These changes also correlate with physiological changes that result in increase in blood pressure and worsening systolic and diastolic performance.
- Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
FIGS. 1A-1B illustrate the progression of heart damage once the build-up of plaque in an artery induces an infarct to occur. -
FIGS. 2A-2G show examples of chemical structures of a functionalized polyethylene glycol. -
FIG. 3 shows a general formula for the chemical structure of a functionalized polyethylene glycol. -
FIG. 4 illustrates an embodiment of a dual bore delivery device. -
FIGS. 5A-5B illustrate an alternative embodiment of a dual bore delivery device. -
FIGS. 6A-6C illustrate a second alternative embodiment of a dual bore delivery device. -
FIGS. 1A-1B illustrate the progression of heart damage once the build-up of plaque induces an infarct to occur.FIG. 1A illustrates asite 10 where blockage and restricted blood flow can occur from, for example, a thrombus or embolus.FIG. 1B illustratesresultant damage area 20 to the left ventricle that can result from the lack of oxygen and nutrient flow carried by the blood to the inferior region left of the heart.Damage area 20 will likely undergo remodeling, and eventually scarring, resulting in a non-functional area. - Bioscaffoldings formed of two components and applied in situ to the left heart ventricle can be used to treat post-myocardial infarction tissue damage. “Bioscaffolding” and “two-component gelation system” and “gelation system” are hereinafter used interchangeably. Examples of two-component gelation systems include, but are not limited to, alginate construct systems, fibrin glues and fibrin glue-like systems, self-assembled peptides, synthetic polymer systems and combinations thereof. Each component of the two-component gelation system may be co-injected to an infarct region by a dual-lumen delivery device. Examples of dual-lumen delivery devices include, but are not limited to, dual-needle left-ventricle injection devices, dual-needle transvascular wall injection devices and the like.
- In some applications, the two-component gelation system includes fibrin glue. Fibrin glue consists of two main components, fibrinogen and thrombin. Fibrinogen is a plasma glycoprotein of about 340 kiloDaltons (kDa) in its endogenous state. Fibrinogen is a symmetrical dimer comprised of six paired polypeptide chains, alpha, beta and gamma chains. On the alpha and beta chains, there is a small peptide sequence called a fibrinopeptide which prevents fibrinogen from spontaneously forming polymers with itself. In some embodiments, fibrinogen is modified with proteins. Thrombin is a coagulation protein. When combined in equal volumes, thrombin converts the fibrinogen to fibrin by enzymatic action at a rate determined by the concentration of thrombin. The result is a biocompatible gel which gelates when combined at the infarct region. Fibrin glue can undergo gelation between about 5 to about 60 seconds. Examples of fibrin glue-like systems include, but are not limited to, Tisseel™ (Baxter), Beriplast P™ (Aventis Behring), Biocol® (LFB, France), Crosseal™ (Omrix Biopharmaceuticals, Ltd.), Hemaseel HMN® (Haemacure Corp.), Bolheal (Kaketsuken Pharma, Japan) and CoStasis® (Angiotech Pharmaceuticals).
- In some applications, the two-component gelation system includes self-assembled peptides. Self-assembled peptides generally include repeat sequences of alternating hydrophobic and hydrophilic amino acid chains. The hydrophilic amino acids are generally charge-bearing and can be anionic, cationic or both. Examples of cationic amino acids are lysine and arginine. Examples of anionic amino acids are aspartic acid and glutamic acid. Examples of hydrophobic amino acids are alanine, valine, leucine, isoleucine or phenylalanine. Self-assembled peptides can range from 8 to 40 amino acids in length and can assemble into nanoscale fibers under conditions of physiological pH and osmolarity. In sufficient concentration and over time, the fibers can assemble into an interconnected structure that appears macroscopically as a gel. Self-assembled peptides typically undergo gelation between several minutes to several hours. Examples of self-assembled peptides include, but are not limited to: AcN-RARADADARARADADA-CNH2 (RAD 16-II) wherein R is arginine, A is alanine, D is aspartic acid, and Ac indicates acetylation; VKVKVKVKV-PP-TKVKVKVKV-NH2 (MAX-1) wherein V is valine, K is lysine and P is proline; and AcN-AEAEAKAKAEAEAKAK-CNH2 wherein A is alanine, K is lysine and E is glutamic acid (EAK16-II).
- In some applications, the two-component gelation system is an alginate construct system. One component may be an alginate conjugate (or alginate alone) which can include alginate and a protein constituent. The second component may be a salt. Examples of alginate conjugates can include, but are not limited to, alginate-collagen, alginate-laminin, alginate-elastin, alginate-collagen-laminin and alginate-hyaluronic acid in which the collagen, laminin, elastin, collagen-laminin or hyaluronic acid is covalently bonded (or not bonded) to alginate. Examples of salts which can be used to gel the alginate constructs include, but are not limited to, calcium chloride (CaCl2), barium chloride (BaCl2) or strontium chloride (SrCl2).
- In one embodiment, the alginate construct is alginate-gelatin. The molecular weight of the gelatin may be in the approximate range of 5 kDa to 100 kDa. The relatively low molecular weight of gelatin offers processing advantages in that it is more soluble and has lower viscosity than hydrogels of higher molecular weight. Another advantage of gelatin is that it contains from 1 to 4 RGD (arginine-glycine-aspartic acid peptide sequence) sites per molecule. RGD is a common cell adhesion ligand and would increase the retention of cells within the infarct zone where the bioscaffolding is formed. The cells retained by the RGD sites may be cells co-injected with the bioscaffolding components or dispersed throughout a component of the system.
- The gelatin may be a porcine gelatin or a recombinant human gelatin. The porcine gelatin is a hydrolyzed
type 1 collagen extracted from porcine skin. In one embodiment, the molecular weight of the porcine gelatin is approximately 20 kDa. The human gelatin is produced by bacteria using human genetic material. The human recombinant gelatin is equivalent to the porcine gelatin but may reduce the likelihood of an immune response when injected into an infarct region of a human subject. - Alginate is a linear polysaccharide derived from seaweed and contains mannuronic (M) and guluronic acid (G), presented in both alternating blocks and alternating individual residues. It is possible to use some of the carboxyl groups of the alginate as sites to graft useful cell adhesion ligands, such as collagen, laminin, elastin and other peptide fragments of the ECM matrix, forming an alginate conjugate, because alginate does not have RGD groups for cell attachment.
- The alginate-gelatin conjugate can be formed of approximately 1% to 30% and more particularly approximately 10% to 20% gelatin (either porcine or human recombinant) and approximately 80% to 90% alginate. A relatively lower proportion of gelatin is used in the conjugate to retain gelation capacity of native alginate because the carboxyl groups of alginate that cause the gelation may be bound up in the alginate-gelatin conjugate.
- In some embodiments, the two-component gelation system includes polyethylene glycols. PEG is a synthetic polymer having the repeating structure (OCH2CH2)n. A first component may be a polyethylene glycol (PEG) polymer functionalized with at least two nucleophilic groups. Examples of nucleophilic groups include, but are not limited to, thiol (—SH), thiol anion (—S−), and amine (—NH2). A “nucleophile” is a reagent which is attracted to centers of positive charge. A nucleophile participates in a chemical reaction by donating electrons to an electrophile in order to form a chemical bond. A second component may be a PEG polymer functionalized with at least two electrophilic groups. Examples of electrophilic groups include, but are not limited to, N-hydroxy succinimide ester (—NHS), acrylate, vinyl sulfone, and maleimide. —NHS, or succinimidyl, is a five-member ring structure represented by the chemical formula —N(COCH2)2. An “electrophile” is a reagent attracted to electrons that participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile. The total number of electrophilic and nucleophilic groups should be greater than 4.
- In some embodiments, two functionalized PEGs comprising a PEG functionalized with at least two nucleophilic groups and a PEG functionalized with at least two electrophilic groups can be combined in a 1:1 ratio. The PEGs can be stored in a 0.01M acidic solution at a pH below about 4.0. At room temperature and standard concentration, reaction and cross-linking between the two functionalized PEGs occurs beginning at approximately pH greater than 6.5. Under these conditions, reaction kinetics are slow. When 0.3 M basic buffer solution at pH about 9.0 is added to the PEGs, gelation occurs in less than 1 minute. This system exhibits poor cytocompatibility due to the low pH of the functionalized PEG solution and the high osmolality pH 9.0 buffer. “Cytocompatibility” refers to the ability of media to provide an environment conducive to cell growth. Additionally, this system does not include any cell adhesion sites.
- In some embodiments, a bioscaffolding is formed from combining functionalized polymers (bioscaffolding precursors) with an extra-cellular matrix (ECM) protein at physiological osmolality. The resulting bioscaffolding can be in a pH range of between about 6.5 and about 7.5. Examples of ECM proteins include, but are not limited to, collagen, laminin, elastin and fragments thereof, in addition to, proteins, protein fragments and peptides with cell adhesion ligands such as RGD groups. In some embodiments, cells can be added to the bioscaffolding precursors. Examples of cell types include, but are not limited to, localized cardiac progenitor cells, mesenchymal stem cells (osteoblasts, chondrocytes and fibroblasts), bone marrow derived mononuclear cells, adipose tissue derived stem cells, embryonic stem cells, umbilical-cord-blood-derived stem cells, smooth muscle cells or skeletal myoblasts. In some embodiments, growth factors can be added to the system. Examples of growth factors include, but are not limited to, isoforms of vasoendothelial growth factor (VEGF), fibroblast growth factor (FGF, e.g. beta-FGF),
Del 1, hypoxia inducing factor (HIF 1-alpha), monocyte chemoattractant protein (MCP-1), nicotine, platelet derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), transforming growth factor (TGF alpha), hepatocyte growth factor (HGF), estrogens, follistatin, proliferin, prostaglandin E1 and E2, tumor necrosis factor (TNF-alpha), interleukin 8 (Il-8), hematopoietic growth factors, erythropoietin, granulocyte-colony stimulating factors (G-CSF) and platelet-derived endothelial growth factor (PD-ECGF). - The polymers can include synthetic polymers, such as polyamino acids, polysaccharides, polyalkylene oxide or polyethylene glycol (PEG). The molecular weight of the compounds can vary depending on the desired application. In most instances, the molecular weight (mol. wt.) is about 100 to about 100,000 mol. wt., and more preferably about 1,000 to about 20,000 mol. wt.
- In some embodiments, the polymer is polyethylene glycol. As used herein, the term “polyethylene glycol(s)” includes modified and/or derivatized polyethylene glycols. According to some embodiments, a first functionalized PEG can be functionalized by at least two reactive groups, such as electrophilic groups. Examples of reactive groups include, but are not limited to, a succinimidyl group (—NHS), a vinyl group, such as acrylate, vinylsulfone, vinyl ether, allyl ether, vinyl ester, vinyl ketone or maleimide, and nitrophenolate or similar leaving group. According to some embodiments, a second functionalized PEG can be functionalized by at least two reactive groups, such as nucleophilic groups. Examples of reactive groups include, but are not limited to, a thiol group, an amino group, a hydroxyl group, phosphine radical (PH2) and —CO—NH—NH2. Representative functionalized PEGs with electrophilic groups are shown in
FIGS. 2A through 2G . A general representative formula for functionalized PEGs with nucleophilic groups are shown inFIG. 3 . In some embodiments a PEG functionalized with electrophilic groups is combined with a PEG functionalized with nucleophilic groups to form a bioscaffolding gel. The total number of electrophilic and nucleophilic groups should be greater than 4. - The branched conformation of the PEGs represented in
FIGS. 2A-2G & 3 is not limiting. In some embodiments, the combined functionality of the PEGs can be greater than four. “Functionality” refers to the number of electrophilic or nucleophilic groups on the polymer core that are capable of reacting with other nucleophilic or electrophilic groups, respectively, to form a gel. That is, as long as the PEGs to be combined are at least difunctional, i.e., each PEG contains at least two nucleophilic or electrophilic groups, the functionalized PEGs can be combined to form a bioscaffolding gel. The total number of electrophilic and nucleophilic groups should therefore be greater than 4. - In some embodiments, a bioscaffolding can include a first component with at least one functionalized PEG and an ECM protein, and a second component of buffer. “Component” hereinafter refers to one part of a two-part system and can include multiple constituents (e.g., a mixture). In one embodiment, the first component can include a mixture of a first functionalized PEG, such as —NHS PEG (or other functionalized PEG with at least two reactive groups), a second functionalized PEG, such as —SH PEG (or other functionalized PEG with at least two reactive groups), and an ECM protein. In some embodiments, the first component can include first functionalized polymer only, such as —NHS PEG (or other functionalized PEG with at least two reactive groups) and an ECM protein.
- In some embodiments, the first functionalized PEG can be combined with the second functionalized PEG in a 1:1 ratio. In some embodiments, e.g., the functionalized PEGs can be combined in a ratio less than 1:1. For example, the two PEGs can have different number of functional groups and, as a result, the PEG stoichiometry could be altered. Alternatively, the crosslinking density may be altered by varying the polymer ratio. In some embodiments, the functionalized PEGs are combined in the solid phase. When preparing to deliver to a treatment site, the mixture can be suspended in a pH 6.5 buffer at approximately physiological osmolality, i.e., 280-300 mOsm/kg H2O. Examples of buffers include, but are not limited to dilute hydrogen chloride and citrate buffers.
- The second component can include a buffer in a pH range from approximately 7.5 to 9.5 at a concentration from about 140 mM to about 150 mM. Examples of buffers include sodium phosphate and sodium carbonate buffers. The buffer can be at approximately physiological osmolality, i.e., 280-300 mOsm/kg H2O. In some embodiments, the second component can include an —SH PEG and the buffer (or other functionalized PEG with at least two reactive groups).
- In some embodiments, a cell type can be added to the first component. Examples of cell types include, but are not limited to, localized cardiac progenitor cells, mesenchymal stem cells (osteoblasts, chondrocytes and fibroblasts), bone marrow derived mononuclear cells, adipose tissue derived stem cells, embryonic stem cells, umbilical-cord-blood-derived stem cells, smooth muscle cells or skeletal myoblasts. For example, human mesenchymal stem cells (hMSC) can be added to the first component. In some embodiments, a growth factor can be added to the first component. In some applications, the functionalized PEGs can react with the growth factors which could stabilize the growth factors, extend their half-life or provide a mode for controlled release of the growth factors. The growth factors can act to help survival of injected hMSC or endogenous progenitor cells at the infarct region. In addition, the growth factors can aid direct endogenous progenitor cells to the injury site.
- In general, cells do not attach to PEG surfaces or gels formed from PEG polymers. That is, PEG polymers do not provide a cytocompatible environment for cells. Collagen or gelatin or any other ECM protein such as fibronectin, may be added to improve cytocompatibility. However, in the case of collagen, for example, the collagen added to the mixture of PEGs can make the mixture very viscous and therefore not conducive with catheter delivery systems. It is anticipated that the pH of the first component and the concentration of the second component, as described in embodiments of the invention, will increase the cytocompatibility of the cell types even with an ECM protein present.
- In some embodiments, the first component can be combined with the second component to produce a bioscaffolding at an infarct region. When combined, the resulting bioscaffolding gel can be at a pH of between 6.8 and 7.4. Although the low buffer concentration of the second component may slow the reaction down, the resulting gel can enable improved cytocompatibility. The ECM protein can provide cell adhesion cites to enable cell spreading and migration. “Cell spreading” refers to the naturally occurring morphology that some cells attain when they are allowed to grow on cytocompatible surfaces. In the case of hMSC, the natural morphology is a flattened, spindle-shaped morphology. In some embodiments, the N-terminus and lysine and arginine side groups of the ECM may react with the —NHS PEG. This may provide better mechanical stability of the gel and reduce the tendency of the gel to swell. This reaction is what forms the gel.
- In some embodiments, the —NHS group of the —NHS PEG can be replaced with a vinyl constituent such as acrylate, vinylsulfone, vinyl ketone, allyl ester, allyl ketone or maleimide group(s). When mixed with an —SH PEG at appropriate conditions, these groups can react with the thiol group(s) of the —SH PEG through a Michael type reaction. Michael type reactions are well known by those skilled in the art. In some embodiments, the reaction could be activated with a buffer in a pH range of between about 6.0 and about 9.0, by a catalytic amount of various amines or a combination thereof. It is anticipated that a Michael type reaction would contribute to the long term stability of the resulting gel since thioether bonds are formed as compared to the more hydrolytically labile thioester bonds formed from the reaction of thiols with activated esters. In some embodiments, the —NHS group of the —NHS PEG can be replaced with a leaving group such as a nitrophenolate.
- In some embodiments, the —SH group of the —SH PEG can be replaced with an amino group to form an amide bond when combined with an —NHS or alternatively functionalized PEG.
- Devices which can be used to deliver each component of the gel include, but are not limited to, dual-needle left-ventricle injection devices, dual-needle transvascular wall injection and dual syringes. Methods of access to use the minimally invasive (i.e., percutaneous or endoscopic) injection devices include access via the femoral artery or the sub-xiphoid. “Xiphoid” or “xiphoid process” is a pointed cartilage attached to the lower end of the breastbone or sternum, the smallest and lowest division of the sternum. Both methods are known by those skilled in the art.
-
FIG. 4 illustrates an embodiment of a dual syringe device which can be used to deliver the compositions of the present invention.Dual syringe 400 can includefirst barrel 410 andsecond barrel 420 adjacent to one another and connected at aproximal end 455,distal end 460 andmiddle region 465 byplates barrels barrel plunger 415 andplunger 425, respectively.Barrels needles barrels Barrels Dual syringe 400 can be constructed of any metal or plastic which is minimally reactive or completely unreactive with the formulations described in the present invention. In some embodiments,dual syringe 400 includes a pre-mixing chamber attached todistal end 465. - In some applications,
first barrel 410 can include a first component of a two-component polyethylene glycol gelation system andsecond barrel 420 can include a second component of the system according to any of the embodiments described previously. A therapeutic amount of the resulting gel is between about 25 μL to about 200 μL, preferably about 50 μL.Dual syringe 400 can be used during, for example, an open chest surgical procedure. -
FIGS. 5A-5B illustrate an embodiment of a dual-needle injection device which can be used to deliver the compositions of the present invention.Delivery assembly 500 includeslumen 510 which may house delivery lumens, guidewire lumens and/or other lumens.Lumen 510, in this example, extends betweendistal portion 505 andproximal end 515 ofdelivery assembly 500. - In one embodiment,
delivery assembly 500 includesfirst needle 520 movably disposed withindelivery lumen 530.Delivery lumen 530 is, for example, a polymer tubing of a suitable material (e.g., polyamides, polyolefins, polyurethanes, etc.).First needle 520 is, for example, a stainless steel hypotube that extends a length of the delivery assembly.First needle 520 includes a lumen with an inside diameter of, for example, 0.08 inches (0.20 centimeters). In one example for a retractable needle catheter,first needle 520 has a needle length on the order of about 40 inches (about 1.6 meters) fromdistal portion 505 toproximal portion 515.Lumen 510 also includesauxiliary lumen 540 extending, in this example, co-linearly along the length of the catheter (from adistal portion 505 to proximal portion 515).Auxiliary lumen 540 is, for example, a polymer tubing of a suitable material (e.g., polyamides, polyolefins, polyurethanes, etc.). Atdistal portion 505,auxiliary lumen 540 is terminated at a delivery end ofsecond needle 550 and co-linearly aligned with a delivery end ofneedle 520.Auxiliary lumen 540 may be terminated to a delivery end ofsecond needle 550 with a radiation-curable adhesive, such as an ultraviolet curable adhesive.Second needle 550 is, for example, a stainless steel hypotube that is joined co-linearly to the end ofmain needle 520 by, for example, solder (illustrated as joint 555).Second needle 550 has a length on the order of about 0.08 inches (0.20 centimeters).FIG. 5B shows a cross-sectional front view through line A-A′ ofdelivery assembly 500.FIG. 5B showsmain needle 520 andsecond needle 550 in a co-linear alignment. - Referring to
FIG. 5A , atproximal portion 515,auxiliary lumen 540 is terminated toauxiliary side arm 460.Auxiliary side arm 560 includes a portion extending co-linearly withmain needle 520.Auxiliary side arm 560 is, for example, a stainless steel hypotube material that may be soldered to main needle 520 (illustrated as joint 565).Auxiliary side arm 560 has a co-linear length on the order of about, in one example, 1.2 inches (3 centimeters). - The proximal end of
main needle 520 includes adaptor 570 for accommodating a substance delivery device (e.g., a component of a two-component bioerodable gel material). Adaptor 570 is, for example, a molded female luer housing. Similarly, a proximal end ofauxiliary side arm 560 includesadaptor 580 to accommodate a substance delivery device (e.g., a female luer housing). - The design configuration described above with respect to
FIGS. 5A-5B is suitable for introducing two-component gel compositions of the present invention. For example, a gel may be formed by a combination (mixing, contact, etc.) of a first component and a second component. Representatively, a first component may be introduced by a one cubic centimeters syringe at adaptor 570 throughmain needle 520. At the same time or shortly before or after, second component including a silk protein and optionally a least one cell type may be introduced with a one cubic centimeter syringe atadaptor 580. When the first and second components combine at the exit of delivery assembly 500 (at an infarct region), the materials combine (mix, contact) to form a bioerodable gel. -
FIGS. 6A-6C illustrate an alternative embodiment of a dual-needle injection device which can be used to deliver two-component gel compositions of the present invention. In general, thecatheter assembly 600 provides a system for delivering substances, such as two-component gel compositions, to or through a desired area of a blood vessel (a physiological lumen) or tissue in order to treat a myocardial infarct region. Thecatheter assembly 600 is similar to thecatheter assembly 600 described in commonly-owned, U.S. Pat. No. 6,554,801, titled “Directional Needle Injection Drug Delivery Device”, which is incorporated herein by reference. - In one embodiment,
catheter assembly 600 is defined byelongated catheter body 650 havingproximal portion 620 anddistal portion 610.Guidewire cannula 670 is formed within catheter body (fromproximal portion 610 to distal portion 620) for allowingcatheter assembly 600 to be fed and maneuvered overguidewire 680.Balloon 630 is incorporated atdistal portion 610 ofcatheter assembly 600 and is in fluid communication withinflation cannula 660 ofcatheter assembly 600. -
Balloon 630 can be formed from balloon wall ormembrane 635 which is selectively inflatable to dilate from a collapsed configuration to a desired and controlled expanded configuration.Balloon 630 can be selectively dilated (inflated) by supplying a fluid intoinflation cannula 660 at a predetermined rate of pressure through inflation port 665 (located at proximal end 620).Balloon wall 635 is selectively deflatable, after inflation, to return to the collapsed configuration or a deflated profile.Balloon 630 may be dilated (inflated) by the introduction of a liquid intoinflation cannula 660. Liquids containing treatment and/or diagnostic agents may also be used to inflateballoon 630. In one embodiment,balloon 630 may be made of a material that is permeable to such treatment and/or diagnostic liquids. To inflateballoon 630, the fluid can be supplied intoinflation cannula 660 at a predetermined pressure, for example, between about one and 20 atmospheres. The specific pressure depends on various factors, such as the thickness ofballoon wall 635, the material from whichballoon wall 635 is made, the type of substance employed and the flow-rate that is desired. -
Catheter assembly 600 also includes at least two substance delivery assemblies 605 a and 605 b (not shown; seeFIGS. 6B-6C ) for injecting a substance into a myocardial infarct region. In one embodiment, substance delivery assembly 605 a includes needle 615 a movably disposed within hollow delivery lumen 625 a. Delivery assembly 605 b includes needle 615 b movably disposed within hollow delivery lumen 625 b (not shown; seeFIGS. 6B-6C ). Delivery lumen 625 a and delivery lumen 625 b each extend betweendistal portion 610 andproximal portion 620. Delivery lumen 625 a and delivery lumen 625 b can be made from any suitable material, such as polymers and copolymers of polyamides, polyolefins, polyurethanes and the like. Access to the proximal end of delivery lumen 625 a or delivery lumen 625 b for insertion of needle 615 a or 615 b, respectively is provided through hub 635 (located at proximal end 620). Delivery lumens 625 a and 625 b may be used to deliver first and second components of a two-component gel composition to a post-myocardial infarct region. -
FIG. 6B shows a cross-section ofcatheter assembly 600 through line A-A′ ofFIG. 6A (at distal portion 610).FIG. 6C shows a cross-section ofcatheter assembly 600 through line B-B′ ofFIG. 6A . In some embodiments, delivery assemblies 605 a and 605 b are adjacent to each other. The proximity of delivery assemblies 605 a and 605 b allows each component of the two-component gelation system to rapidly gel when delivered to a treatment site, such as a post-myocardial infarct region. - From the foregoing detailed description, it will be evident that there are a number of changes, adaptations and modifications of the present invention which come within the province of those skilled in the part. The scope of the invention includes any combination of the elements from the different species and embodiments disclosed herein, as well as subassemblies, assemblies and methods thereof. However, it is intended that all such variations not departing from the spirit of the invention be considered as within the scope thereof.
Claims (20)
1. A composition comprising:
a first mixture comprising a first functionalized polymer in a first buffer at approximately physiological osmolality;
a second buffer at approximately physiological osmolality;
a second functionalized polymer, wherein the second functionalized polymer is combined with one of the first mixture or the second buffer; and
a substance having at least one cell-adhesion site combined with the first mixture,
wherein the first mixture and the second buffer comprise a gel at pH 7.2 when combined.
2. The composition of claim 1 , wherein the first functionalized polymer is one of an activated ester-terminated polyethylene glycol or a vinyl-terminated polyethylene glycol.
3. The composition of claim 1 , wherein the second functionalized polymer is one of a thiol-terminated polyethylene glycol or an amino-terminated polyethylene glycol.
4. The composition of claim 1 , wherein the substance is a protein selected from the group consisting of gelatin, laminin, elastin, arginine-glycine-aspartic acid peptide sequence and peptide fragments thereof.
5. The composition of claim 1 , wherein the first mixture further comprises one of a cell type, a growth factor or a combination thereof.
6. The composition of claim 1 , wherein the first functionalized polymer and the second functionalized polymer has a functionality greater than four.
7. A kit comprising:
a first syringe including a first functionalized polymer and a substance having at least one cell-adhesion site in a first buffer at physiological osmolality; and
a second syringe including a second buffer at physiological osmolality.
8. The kit of claim 7 , wherein the first functionalized polymer is one of an activated ester-terminated polyethylene glycol or a vinyl-terminated polyethylene glycol.
9. The kit of claim 7 , wherein the second functionalized polymer is one of a thiol-terminated polyethylene glycol or an amino-terminated polyethylene glycol.
10. The kit of claim 7 , wherein the substance is a protein selected from the group consisting of gelatin, laminin, elastin, arginine-glycine-aspartic acid peptide sequence and peptide fragments thereof.
11. The kit of claim 7 , wherein the first mixture further comprises one of a cell type, a growth factor or a combination thereof.
12. A method of treatment comprising:
simultaneously injecting from a dual bore delivery device (a) a first mixture comprising a first functionalized polymer and a substance having at least one cell-adhesion site in a first buffer at physiological osmolality and (b) a second buffer at physiological osmolality to a post-myocardial infarct region.
13. The method of claim 12 , further comprising a second functionalized polymer, wherein the second functionalized polymer is combined with one of the first mixture or the second buffer.
14. The method of claim 12 , wherein the first functionalized polymer r is one of an activated ester-terminated polyethylene glycol or a vinyl-terminated polyethylene glycol.
15. The method of claim 13 , wherein the second functionalized polymer is one of a thiol-terminated polyethylene glycol or an amino-terminated polyethylene glycol.
16. The method of claim 12 , wherein the substance is a protein selected from the group consisting of gelatin, laminin, elastin, arginine-glycine-aspartic acid peptide sequence and peptide fragments thereof.
17. The method of claim 12 , wherein the first mixture further comprises one of a cell type, a growth factor or a combination thereof.
18. The method of claim 17 , wherein the cell type, the growth factor, or the combination thereof is combined with the first mixture.
19. The method of claim 13 , wherein the first functionalized polymer and the second functionalized polymer has a functionality greater than four.
20. The method of claim 13 , wherein the first mixture and the second buffer comprise a gel at pH 7.2 when combined.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/941,759 US20140017200A1 (en) | 2006-07-31 | 2013-07-15 | Modified two-component gelation systems, methods of use and methods of manufacture |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/496,824 US7732190B2 (en) | 2006-07-31 | 2006-07-31 | Modified two-component gelation systems, methods of use and methods of manufacture |
US12/756,092 US8486386B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
US12/756,119 US8486387B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
US13/941,759 US20140017200A1 (en) | 2006-07-31 | 2013-07-15 | Modified two-component gelation systems, methods of use and methods of manufacture |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/756,092 Continuation US8486386B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140017200A1 true US20140017200A1 (en) | 2014-01-16 |
Family
ID=38673478
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/496,824 Expired - Fee Related US7732190B2 (en) | 2006-07-31 | 2006-07-31 | Modified two-component gelation systems, methods of use and methods of manufacture |
US12/756,092 Expired - Fee Related US8486386B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
US12/756,119 Expired - Fee Related US8486387B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
US13/941,759 Abandoned US20140017200A1 (en) | 2006-07-31 | 2013-07-15 | Modified two-component gelation systems, methods of use and methods of manufacture |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/496,824 Expired - Fee Related US7732190B2 (en) | 2006-07-31 | 2006-07-31 | Modified two-component gelation systems, methods of use and methods of manufacture |
US12/756,092 Expired - Fee Related US8486386B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
US12/756,119 Expired - Fee Related US8486387B2 (en) | 2006-07-31 | 2010-04-07 | Modified two-component gelation systems, methods of use and methods of manufacture |
Country Status (4)
Country | Link |
---|---|
US (4) | US7732190B2 (en) |
EP (2) | EP2068830A2 (en) |
JP (2) | JP2009545372A (en) |
WO (1) | WO2008016490A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10722631B2 (en) | 2018-02-01 | 2020-07-28 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
US11185677B2 (en) | 2017-06-07 | 2021-11-30 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
US11511103B2 (en) | 2017-11-13 | 2022-11-29 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
US11724089B2 (en) | 2019-09-25 | 2023-08-15 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1041032C (en) * | 1993-04-03 | 1998-12-02 | 施内德电气公司 | Unit for connecting of model low voltage breaker |
US6702744B2 (en) * | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US8038991B1 (en) | 2003-04-15 | 2011-10-18 | Abbott Cardiovascular Systems Inc. | High-viscosity hyaluronic acid compositions to treat myocardial conditions |
US8821473B2 (en) * | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
US8303972B2 (en) * | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
US8187621B2 (en) * | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
US8828433B2 (en) * | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US7732190B2 (en) * | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US9005672B2 (en) * | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US8741326B2 (en) * | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
US9358369B1 (en) | 2008-08-13 | 2016-06-07 | Abbott Cardiovascular Systems Inc. | Reduced profile and enhanced flexibility delivery catheters for light activated agents |
US9370306B1 (en) | 2008-08-13 | 2016-06-21 | Abbott Cardiovascular System Inc. | Methods and devices for in vivo targeted light therapy |
US8170657B1 (en) | 2008-08-13 | 2012-05-01 | Abbott Cadiovascular Systems Inc. | Delivery catheters for light activated agents |
US9445795B2 (en) * | 2009-10-16 | 2016-09-20 | Confluent Surgical, Inc. | Prevention of premature gelling of delivery devices for pH dependent forming materials |
US8372054B2 (en) * | 2009-10-27 | 2013-02-12 | Medtronic Vascular, Inc. | Over-the-wire balloon catheter for efficient targeted cell delivery |
WO2013106655A1 (en) | 2012-01-11 | 2013-07-18 | The Gid Group, Inc. | Method for processing adipose tissue and processing apparatus |
US9206387B2 (en) | 2010-07-09 | 2015-12-08 | The Gid Group, Inc. | Method and apparatus for processing adipose tissue |
US9260697B2 (en) | 2010-07-09 | 2016-02-16 | The Gid Group, Inc. | Apparatus and methods relating to collecting and processing human biological material containing adipose |
US9296984B2 (en) | 2010-07-09 | 2016-03-29 | The Gid Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
US8524215B2 (en) | 2010-08-02 | 2013-09-03 | Janssen Biotech, Inc. | Absorbable PEG-based hydrogels |
US8377033B2 (en) | 2010-09-08 | 2013-02-19 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
JP6188285B2 (en) * | 2012-07-13 | 2017-08-30 | キヤノン株式会社 | Image processing apparatus, image processing apparatus control method, and program |
EP3075841B1 (en) | 2012-09-06 | 2021-03-10 | GID BIO, Inc. | Tissue processing apparatus and method for processing adipose tissue |
EP2938323A2 (en) | 2012-12-28 | 2015-11-04 | Abbott Cardiovascular Systems, Inc. | Therapeutic compositions comprising antibodies |
US20150064143A1 (en) * | 2013-09-04 | 2015-03-05 | Industry-University Cooperation Foundation Hanyang University | Ionically cross-linkable alginate-grafted hyaluronate compound |
EP3038629B1 (en) | 2013-09-05 | 2020-11-18 | GID BIO, Inc. | Method for processing adipose tissue |
EP3137139A1 (en) | 2014-05-02 | 2017-03-08 | Lifecell Corporation | Injection sensor with feedback mechanism |
BR112018008059A2 (en) | 2015-10-21 | 2018-10-23 | Lifecell Corp | medical device control systems and methods |
CA3002078A1 (en) | 2015-10-21 | 2017-04-27 | Lifecell Corporation | Systems and methods for tube management |
CA3008035A1 (en) | 2015-12-22 | 2017-06-29 | Lifecell Corporation | Syringe filling device for fat transfer |
JP2019526342A (en) | 2016-08-30 | 2019-09-19 | ライフセル コーポレーションLifeCell Corporation | System and method for controlling medical devices |
US20180085555A1 (en) * | 2016-09-26 | 2018-03-29 | Boston Scientific Scimed, Inc. | Injection catheter |
USD851777S1 (en) | 2017-01-30 | 2019-06-18 | Lifecell Corporation | Canister-type device for tissue processing |
WO2019018002A1 (en) | 2017-07-18 | 2019-01-24 | The Gid Group, Inc. | Adipose tissue digestion system and tissue processing method |
KR20210089406A (en) | 2020-01-08 | 2021-07-16 | 주식회사 에스앤에스텍 | Reflective type Blankmask for EUV, and Method for manufacturing the same |
Family Cites Families (268)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2194144B (en) | 1986-08-22 | 1990-04-25 | American Cyanamid Co | Stable pharmaceutical gel preparation |
US2512569A (en) | 1947-09-26 | 1950-06-20 | Jacob A Saffir | Hypodermic needle |
US3144868A (en) | 1960-10-21 | 1964-08-18 | Mario E Jascalevich | Drainage and feeding cannulae |
US3584624A (en) * | 1969-02-24 | 1971-06-15 | Vincent L De Ciutiis | Flexible intravenous catheter provided with cutting tip means |
US3780733A (en) | 1972-07-24 | 1973-12-25 | Manzor M Martinez | Catheter |
US3890976A (en) * | 1972-10-26 | 1975-06-24 | Medical Products Corp | Catheter tip assembly |
US3804097A (en) * | 1972-12-14 | 1974-04-16 | P Rudie | Method of irrigating and treating an abcess |
US6436135B1 (en) | 1974-10-24 | 2002-08-20 | David Goldfarb | Prosthetic vascular graft |
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
JPS60126170A (en) * | 1983-12-14 | 1985-07-05 | テルモ株式会社 | Catheter and its production |
US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4617186A (en) | 1984-12-28 | 1986-10-14 | Alcon Laboratories, Inc. | Sustained release drug delivery system utilizing bioadhesive polymers |
US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
US4794931A (en) * | 1986-02-28 | 1989-01-03 | Cardiovascular Imaging Systems, Inc. | Catheter apparatus, system and method for intravascular two-dimensional ultrasonography |
US5026350A (en) | 1986-10-09 | 1991-06-25 | Hakko Electric Machine Works Co., Ltd. | Set of double needles for injecting liquid medicine |
CH673117A5 (en) * | 1986-12-10 | 1990-02-15 | Ajinomoto Kk | |
FR2627984B1 (en) | 1988-03-03 | 1990-08-17 | Sanofi Sa | PULVERULENT COMPOSITION BASED ON ALGINATE FOR DENTAL IMPRESSIONS |
US5588432A (en) | 1988-03-21 | 1996-12-31 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
US5372138A (en) | 1988-03-21 | 1994-12-13 | Boston Scientific Corporation | Acousting imaging catheters and the like |
US5116317A (en) | 1988-06-16 | 1992-05-26 | Optimed Technologies, Inc. | Angioplasty catheter with integral fiber optic assembly |
US5749915A (en) | 1988-08-24 | 1998-05-12 | Focal, Inc. | Polymeric endoluminal paving process |
US5575815A (en) | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
DE68922497T2 (en) | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US5092848A (en) * | 1988-10-13 | 1992-03-03 | Deciutiis Vincent L | Intravenous catheter with built-in cutting tip and method for making the same |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5049130A (en) | 1988-12-23 | 1991-09-17 | Cardiovascular Imaging Systems, Inc. | System and method for pressure filling of catheters |
DE3908183C5 (en) * | 1989-03-14 | 2005-01-05 | Kiekert Ag | Motor vehicle door lock |
US5109859A (en) * | 1989-10-04 | 1992-05-05 | Beth Israel Hospital Association | Ultrasound guided laser angioplasty |
US5024234A (en) * | 1989-10-17 | 1991-06-18 | Cardiovascular Imaging Systems, Inc. | Ultrasonic imaging catheter with guidewire channel |
US5485486A (en) * | 1989-11-07 | 1996-01-16 | Qualcomm Incorporated | Method and apparatus for controlling transmission power in a CDMA cellular mobile telephone system |
AU6747790A (en) | 1989-11-13 | 1991-06-13 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
FR2668698B1 (en) | 1990-11-06 | 1997-06-06 | Ethnor | SURGICAL INSTRUMENT FORMING TROCART. |
US5202745A (en) * | 1990-11-07 | 1993-04-13 | Hewlett-Packard Company | Polarization independent optical coherence-domain reflectometry |
JP3367666B2 (en) * | 1990-12-17 | 2003-01-14 | カーディオヴァスキュラー イメイジング システムズ インコーポレイテッド | Vascular catheter with low profile distal end |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US6134003A (en) | 1991-04-29 | 2000-10-17 | Massachusetts Institute Of Technology | Method and apparatus for performing optical measurements using a fiber optic imaging guidewire, catheter or endoscope |
JP3479069B2 (en) | 1991-04-29 | 2003-12-15 | マサチューセッツ・インステチュート・オブ・テクノロジー | Method and apparatus for optical imaging and measurement |
US5465147A (en) | 1991-04-29 | 1995-11-07 | Massachusetts Institute Of Technology | Method and apparatus for acquiring images using a ccd detector array and no transverse scanner |
SE9101853D0 (en) | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | IMPROVED TISSUE ASHESIVE |
US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5291267A (en) * | 1992-01-22 | 1994-03-01 | Hewlett-Packard Company | Optical low-coherence reflectometry using optical amplification |
EP0626823B1 (en) | 1992-02-21 | 2000-04-19 | Boston Scientific Limited | Ultrasound imaging guidewire |
US6231881B1 (en) | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
ZA932272B (en) * | 1992-03-30 | 1993-10-19 | Alza Corp | Viscous suspensions of controlled-release drug particles |
US5306250A (en) * | 1992-04-02 | 1994-04-26 | Indiana University Foundation | Method and apparatus for intravascular drug delivery |
JP3063935B2 (en) | 1992-05-12 | 2000-07-12 | 宇部興産株式会社 | Polyimide siloxane composition having adhesiveness, heat resistance and curl resistance |
US5336252A (en) | 1992-06-22 | 1994-08-09 | Cohen Donald M | System and method for implanting cardiac electrical leads |
US5365325A (en) | 1992-08-10 | 1994-11-15 | Hitachi, Ltd. | Method of multi-color recording using electro-photography process and apparatus therefor wherein mixed colors generation is prevented |
US5672153A (en) | 1992-08-12 | 1997-09-30 | Vidamed, Inc. | Medical probe device and method |
DE4235506A1 (en) | 1992-10-21 | 1994-04-28 | Bavaria Med Tech | Drug injection catheter |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6689608B1 (en) * | 1993-02-01 | 2004-02-10 | Massachusetts Institute Of Technology | Porous biodegradable polymeric materials for cell transplantation |
EP2025353A2 (en) * | 1993-04-30 | 2009-02-18 | Massachusetts Institute of Technology | Injectable polysaccharide-cell compositions |
US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5437632A (en) | 1993-06-02 | 1995-08-01 | Target Therapeutics, Inc. | Variable stiffness balloon catheter |
US5725551A (en) | 1993-07-26 | 1998-03-10 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5527322A (en) * | 1993-11-08 | 1996-06-18 | Perclose, Inc. | Device and method for suturing of internal puncture sites |
JP2833456B2 (en) * | 1993-11-22 | 1998-12-09 | 株式会社東芝 | Insertable ultrasound system |
US5380292A (en) * | 1993-12-22 | 1995-01-10 | Wilson-Cook Medical, Inc. | Gastrointestinal needle mechanism |
US5795331A (en) | 1994-01-24 | 1998-08-18 | Micro Therapeutics, Inc. | Balloon catheter for occluding aneurysms of branch vessels |
FR2715855A1 (en) | 1994-02-10 | 1995-08-11 | Floch Serge | Protector for syringe used with beta-radiation emitter |
US6334872B1 (en) * | 1994-02-18 | 2002-01-01 | Organogenesis Inc. | Method for treating diseased or damaged organs |
DE4408108A1 (en) * | 1994-03-10 | 1995-09-14 | Bavaria Med Tech | Catheter for injecting a fluid or a drug |
US5464395A (en) | 1994-04-05 | 1995-11-07 | Faxon; David P. | Catheter for delivering therapeutic and/or diagnostic agents to the tissue surrounding a bodily passageway |
WO1995028412A1 (en) | 1994-04-13 | 1995-10-26 | Biotransplant, Inc. | α(1,3) GALACTOSYLTRANSFERASE NEGATIVE SWINE |
DE69534640T2 (en) * | 1994-04-29 | 2006-08-10 | Scimed Life Systems, Inc., Maple Grove | Stent with collagen |
US6056744A (en) * | 1994-06-24 | 2000-05-02 | Conway Stuart Medical, Inc. | Sphincter treatment apparatus |
US5621610A (en) * | 1994-06-30 | 1997-04-15 | Compaq Computer Corporation | Collapsible computer keyboard structure with associated collapsible pointing stick |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
IL110367A (en) * | 1994-07-19 | 2007-05-15 | Colbar Lifescience Ltd | Collagen-based matrix |
US6152141A (en) | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US5740808A (en) * | 1996-10-28 | 1998-04-21 | Ep Technologies, Inc | Systems and methods for guilding diagnostic or therapeutic devices in interior tissue regions |
WO1996011671A1 (en) * | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US6099864A (en) | 1994-12-02 | 2000-08-08 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | In situ activation of microcapsules |
FR2727692A1 (en) * | 1994-12-05 | 1996-06-07 | Europ Propulsion | GAS EXTRACTION DEVICE FOR A CHEMICAL STEAM INFILTRATION OVEN OR VAPOR DEPOSIT IN A PLANT FOR MANUFACTURING PARTS OF COMPOSITE MATERIAL |
CA2208554A1 (en) | 1994-12-28 | 1996-07-04 | Omrix Biopharmaceuticals S.A. | Device for applying one or several fluids |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US5551427A (en) | 1995-02-13 | 1996-09-03 | Altman; Peter A. | Implantable device for the effective elimination of cardiac arrhythmogenic sites |
US5869127A (en) | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5580714A (en) * | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
US5669883A (en) | 1995-04-12 | 1997-09-23 | Symbiosis Corporation | Veress needle and cannula assembly |
US6251104B1 (en) * | 1995-05-10 | 2001-06-26 | Eclipse Surgical Technologies, Inc. | Guiding catheter system for ablating heart tissue |
US5919449A (en) | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
US5900433A (en) * | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
US6102904A (en) | 1995-07-10 | 2000-08-15 | Interventional Technologies, Inc. | Device for injecting fluid into a wall of a blood vessel |
US5693029A (en) | 1995-07-10 | 1997-12-02 | World Medical Manufacturing Corporation | Pro-cell intra-cavity therapeutic agent delivery device |
US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
WO1997012629A1 (en) | 1995-10-05 | 1997-04-10 | Genentech, Inc. | Improved angiogenesis using hepatocyte growth factor |
US6190353B1 (en) * | 1995-10-13 | 2001-02-20 | Transvascular, Inc. | Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures |
US6726677B1 (en) * | 1995-10-13 | 2004-04-27 | Transvascular, Inc. | Stabilized tissue penetrating catheters |
US5642234A (en) * | 1995-10-30 | 1997-06-24 | Lumatec Industries, Inc. | Illuminated magnifying lens assembly |
US6482231B1 (en) | 1995-11-20 | 2002-11-19 | Giovanni Abatangelo | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative |
US6458889B1 (en) * | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
EP1704878B1 (en) * | 1995-12-18 | 2013-04-10 | AngioDevice International GmbH | Crosslinked polymer compositions and methods for their use |
JP2000502682A (en) | 1995-12-22 | 2000-03-07 | ローカルメッド インコーポレイテッド | Local intravascular delivery of growth factors that promote angiogenesis |
US6632436B2 (en) | 1996-01-25 | 2003-10-14 | Genitrix Llc | Vaccine compositions and method of modulating immune responses |
WO1997045105A1 (en) | 1996-05-24 | 1997-12-04 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
WO1997045532A1 (en) | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
US5785689A (en) * | 1996-07-18 | 1998-07-28 | Act Medical, Inc. | Endoscopic catheter sheath position control |
US5655548A (en) | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US5957941A (en) | 1996-09-27 | 1999-09-28 | Boston Scientific Corporation | Catheter system and drive assembly thereof |
US5827313A (en) | 1996-09-27 | 1998-10-27 | Boston Scientific Corporation | Device for controlled longitudinal movement of an operative element within a catheter sheath and method |
US5722403A (en) * | 1996-10-28 | 1998-03-03 | Ep Technologies, Inc. | Systems and methods using a porous electrode for ablating and visualizing interior tissue regions |
US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
EP0842640A1 (en) | 1996-11-13 | 1998-05-20 | Sulzer Osypka GmbH | Heart catheter with electrode positioned on a distensible element |
ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US6120520A (en) | 1997-05-27 | 2000-09-19 | Angiotrax, Inc. | Apparatus and methods for stimulating revascularization and/or tissue growth |
US6102926A (en) | 1996-12-02 | 2000-08-15 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use |
US5730732A (en) * | 1996-12-04 | 1998-03-24 | Ethicon, Inc. | Non-magnetic stainless steel surgical needle |
US5935160A (en) | 1997-01-24 | 1999-08-10 | Cardiac Pacemakers, Inc. | Left ventricular access lead for heart failure pacing |
JP3134287B2 (en) | 1997-01-30 | 2001-02-13 | 株式会社ニッショー | Catheter assembly for endocardial suture surgery |
US5980551A (en) * | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US5968064A (en) | 1997-02-28 | 1999-10-19 | Lumend, Inc. | Catheter system for treating a vascular occlusion |
US6045565A (en) * | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
US6093177A (en) | 1997-03-07 | 2000-07-25 | Cardiogenesis Corporation | Catheter with flexible intermediate section |
US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
US6443949B2 (en) | 1997-03-13 | 2002-09-03 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
EP0971641A4 (en) * | 1997-04-03 | 2003-08-13 | Point Biomedical Corp | Intravesical drug delivery system |
US5984908A (en) | 1997-04-10 | 1999-11-16 | Chase Medical Inc | Venous return catheter having integral support member |
US6099832A (en) * | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
DE19734220C2 (en) | 1997-08-07 | 2000-01-13 | Pulsion Verwaltungs Gmbh & Co | Catheter system with an insertion wire |
EP1009317A4 (en) | 1997-08-28 | 2001-01-24 | Boston Scient Corp | System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber |
WO1999011287A1 (en) * | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
US6050949A (en) * | 1997-09-22 | 2000-04-18 | Scimed Life Systems, Inc. | Catheher system having connectable distal and proximal portions |
US6179809B1 (en) * | 1997-09-24 | 2001-01-30 | Eclipse Surgical Technologies, Inc. | Drug delivery catheter with tip alignment |
US6183444B1 (en) * | 1998-05-16 | 2001-02-06 | Microheart, Inc. | Drug delivery module |
US6371935B1 (en) * | 1999-01-22 | 2002-04-16 | Cardeon Corporation | Aortic catheter with flow divider and methods for preventing cerebral embolization |
JP2003506310A (en) | 1997-10-07 | 2003-02-18 | リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Treatment of occlusive peripheral vascular disease and coronary artery disease with a combination of heparin and an adenosine A2 agonist or with adenosine |
IL122153A (en) * | 1997-11-10 | 2005-03-20 | Alomone Labs Ltd | Biocompatible polymeric coating material |
US6146373A (en) | 1997-10-17 | 2000-11-14 | Micro Therapeutics, Inc. | Catheter system and method for injection of a liquid embolic composition and a solidification agent |
US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
US6749617B1 (en) * | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
US6151525A (en) | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
US6183432B1 (en) * | 1997-11-13 | 2001-02-06 | Lumend, Inc. | Guidewire and catheter with rotating and reciprocating symmetrical or asymmetrical distal tip |
US6197324B1 (en) * | 1997-12-18 | 2001-03-06 | C. R. Bard, Inc. | System and methods for local delivery of an agent |
US6217527B1 (en) * | 1998-09-30 | 2001-04-17 | Lumend, Inc. | Methods and apparatus for crossing vascular occlusions |
US6371992B1 (en) * | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
US6231546B1 (en) * | 1998-01-13 | 2001-05-15 | Lumend, Inc. | Methods and apparatus for crossing total occlusions in blood vessels |
US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
DE69900746T2 (en) * | 1998-01-30 | 2002-08-14 | Scios Inc | CONTROLLED ADMINISTRATION OF PEPTIDES OR PROTEINS |
ES2293473T3 (en) | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | INTRACARDIAC ADMINISTRATION OF FARMACO. |
EP0938871A3 (en) | 1998-02-27 | 2001-03-07 | ECLIPSE SURGICAL TECHNOLOGIES, Inc. | Surgical apparatus |
US6201608B1 (en) * | 1998-03-13 | 2001-03-13 | Optical Biopsy Technologies, Inc. | Method and apparatus for measuring optical reflectivity and imaging through a scattering medium |
US6175669B1 (en) * | 1998-03-30 | 2001-01-16 | The Regents Of The Universtiy Of California | Optical coherence domain reflectometry guidewire |
CA2324304A1 (en) * | 1998-03-31 | 1999-10-07 | Patrick E. Macaulay | Catheters, systems and methods for percutaneous in situ arterio-venous bypass |
US5979449A (en) | 1998-04-09 | 1999-11-09 | Steer; Eugene Lyle | Oral appliance device and method for use thereof for appetite suppression |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
WO1999056663A2 (en) * | 1998-05-05 | 1999-11-11 | Scimed Life Systems, Inc. | Stent with smooth ends |
US6447504B1 (en) | 1998-07-02 | 2002-09-10 | Biosense, Inc. | System for treatment of heart tissue using viability map |
US6102887A (en) * | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
CA2339330A1 (en) * | 1998-08-13 | 2000-02-24 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6191144B1 (en) * | 1998-08-17 | 2001-02-20 | Warner-Lambert Company | Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis |
AU771367B2 (en) | 1998-08-20 | 2004-03-18 | Cook Medical Technologies Llc | Coated implantable medical device |
AU758178B2 (en) | 1998-09-04 | 2003-03-20 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
US6044298A (en) * | 1998-10-13 | 2000-03-28 | Cardiac Pacemakers, Inc. | Optimization of pacing parameters based on measurement of integrated acoustic noise |
US6162202A (en) | 1998-10-26 | 2000-12-19 | Sicurelli; Robert | Flexible syringe needle |
CA2349168C (en) | 1998-11-10 | 2009-01-06 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, method of its production and medical material containing it |
US6761887B1 (en) | 1998-11-16 | 2004-07-13 | Osiris Therapeutics, Inc. | Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells |
DE19855890A1 (en) * | 1998-12-03 | 2000-06-08 | Nerlich Michael | Porous composite matrix, its production and use |
EP1054703B1 (en) | 1998-12-09 | 2004-09-15 | Cook Incorporated | Hollow, curved, superelastic medical needle |
US6193763B1 (en) * | 1998-12-17 | 2001-02-27 | Robert A. Mackin | Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue |
US6328229B1 (en) | 1998-12-18 | 2001-12-11 | Cohesion Technologies, Inc. | Low volume mixing spray head for mixing and dispensing of two reactive fluid components |
US6338717B1 (en) | 1998-12-22 | 2002-01-15 | Asahi Kogaku Kogyo Kabushiki Kaisha | Tip of ultrasonic endoscope |
US6210392B1 (en) * | 1999-01-15 | 2001-04-03 | Interventional Technologies, Inc. | Method for treating a wall of a blood vessel |
AU3347000A (en) | 1999-01-19 | 2000-08-01 | Children's Hospital Of Philadelphia, The | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
US6217528B1 (en) * | 1999-02-11 | 2001-04-17 | Scimed Life Systems, Inc. | Loop structure having improved tissue contact capability |
US6217554B1 (en) * | 1999-02-12 | 2001-04-17 | Pharmaspec Corporation | Methods and apparatus for delivering substances into extravascular tissue |
US20020081732A1 (en) | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
US20020090725A1 (en) | 2000-11-17 | 2002-07-11 | Simpson David G. | Electroprocessed collagen |
US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
JP3678602B2 (en) * | 1999-03-17 | 2005-08-03 | 住友ベークライト株式会社 | Syringe fixed injection device |
US6296602B1 (en) | 1999-03-17 | 2001-10-02 | Transfusion Technologies Corporation | Method for collecting platelets and other blood components from whole blood |
US6432119B1 (en) | 1999-03-17 | 2002-08-13 | Angiotrax, Inc. | Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials |
US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
US6192271B1 (en) | 1999-04-20 | 2001-02-20 | Michael Hayman | Radiotherapy stent |
US6858229B1 (en) * | 1999-04-26 | 2005-02-22 | California Institute Of Technology | In situ forming hydrogels |
US6159443A (en) | 1999-04-29 | 2000-12-12 | Vanderbilt University | X-ray guided drug delivery |
JP3063935U (en) * | 1999-05-17 | 1999-12-10 | 川澄化学工業株式会社 | Two-component simultaneous mixing dispenser and plunger coupling member |
US6283947B1 (en) | 1999-07-13 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US6494862B1 (en) | 1999-07-13 | 2002-12-17 | Advanced Cardiovascular Systems, Inc. | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
CA2381772C (en) * | 1999-07-22 | 2006-05-02 | Schlumberger Technology Corporation | Components and methods for use with explosives |
US7815590B2 (en) | 1999-08-05 | 2010-10-19 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
EP2093245B1 (en) * | 1999-08-27 | 2012-02-22 | AngioDevice International GmbH | Biocompatible polymer device |
US6358258B1 (en) * | 1999-09-14 | 2002-03-19 | Abbott Laboratories | Device and method for performing end-to-side anastomosis |
US6385476B1 (en) * | 1999-09-21 | 2002-05-07 | Biosense, Inc. | Method and apparatus for intracardially surveying a condition of a chamber of a heart |
US20040229856A1 (en) | 1999-09-21 | 2004-11-18 | Baskaran Chandrasekar | Local delivery of 17-beta estradiol for preventing vascular intimal hyperplasia and for improving vascular endothelium function after vascular injury |
US6368285B1 (en) * | 1999-09-21 | 2002-04-09 | Biosense, Inc. | Method and apparatus for mapping a chamber of a heart |
AU766208B2 (en) | 1999-09-21 | 2003-10-09 | Institut De Cardiologie De Montreal | Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
US6916488B1 (en) | 1999-11-05 | 2005-07-12 | Biocure, Inc. | Amphiphilic polymeric vesicles |
US6748258B1 (en) * | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
US6992172B1 (en) * | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
US6360129B1 (en) * | 1999-12-13 | 2002-03-19 | Cardiac Pacemakers, Inc. | Mannitol/hydrogel cap for tissue-insertable connections |
US6241710B1 (en) * | 1999-12-20 | 2001-06-05 | Tricardia Llc | Hypodermic needle with weeping tip and method of use |
US6706034B1 (en) * | 1999-12-30 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Process for agent retention in biological tissues |
US6346098B1 (en) * | 2000-03-07 | 2002-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and kits for locally administering an active agent to an interstitial space of a host |
AUPQ618400A0 (en) | 2000-03-13 | 2000-04-06 | Baramy Engineering Pty Ltd | A gross pollutant trap |
US6458098B1 (en) | 2000-03-17 | 2002-10-01 | Nozomu Kanesaka | Vascular therapy device |
EP1136033B1 (en) * | 2000-03-21 | 2004-11-10 | Radi Medical Systems Ab | Passive biotelemetry |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US6589549B2 (en) * | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6875441B2 (en) | 2000-06-26 | 2005-04-05 | Rxkinetix, Inc. | Composition for delivery of hematopoietic growth factor |
WO2002009792A1 (en) * | 2000-07-28 | 2002-02-07 | Anika Therapeutics, Inc. | Bioabsorbable composites of derivatized hyaluronic acid |
US6478775B1 (en) | 2000-10-02 | 2002-11-12 | Genyx Medical Inc. | Device for delivering non-biodegradable bulking composition to a urological site |
US6554801B1 (en) * | 2000-10-26 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Directional needle injection drug delivery device and method of use |
US20020072706A1 (en) * | 2000-12-11 | 2002-06-13 | Thomas Hiblar | Transluminal drug delivery catheter |
US6692466B1 (en) * | 2000-12-21 | 2004-02-17 | Advanced Cardiovascular Systems, Inc. | Drug delivery catheter with retractable needle |
US6599267B1 (en) | 2000-12-22 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Transluminal injection device for intravascular drug delivery |
US6602241B2 (en) | 2001-01-17 | 2003-08-05 | Transvascular, Inc. | Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites |
US6612977B2 (en) * | 2001-01-23 | 2003-09-02 | American Medical Systems Inc. | Sling delivery system and method of use |
US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
CN100336489C (en) | 2001-02-28 | 2007-09-12 | 雷克斯医疗公司 | Apparatus for delivering ablation fluid to treat neoplasms |
WO2002072191A2 (en) | 2001-03-12 | 2002-09-19 | Chachques Juan C | Method of providing a dynamic cellular cardiac support |
WO2002072166A1 (en) * | 2001-03-13 | 2002-09-19 | Biocure, Inc. | Compositions for drug delivery |
WO2002078439A2 (en) | 2001-03-30 | 2002-10-10 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Prevascularized constructs for implantation to provide blood perfusion |
US7396582B2 (en) | 2001-04-06 | 2008-07-08 | Advanced Cardiovascular Systems, Inc. | Medical device chemically modified by plasma polymerization |
US6628988B2 (en) | 2001-04-27 | 2003-09-30 | Cardiac Pacemakers, Inc. | Apparatus and method for reversal of myocardial remodeling with electrical stimulation |
US7311731B2 (en) * | 2001-04-27 | 2007-12-25 | Richard C. Satterfield | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US20020188170A1 (en) | 2001-04-27 | 2002-12-12 | Santamore William P. | Prevention of myocardial infarction induced ventricular expansion and remodeling |
US6660034B1 (en) * | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US6702744B2 (en) * | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
US6723067B2 (en) * | 2001-07-26 | 2004-04-20 | David H. Nielson | Apparatus for delivering aerosolized fibrin endoscopically to a wound |
US6746635B2 (en) | 2001-08-08 | 2004-06-08 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
US6663596B2 (en) | 2001-08-13 | 2003-12-16 | Scimed Life Systems, Inc. | Delivering material to a patient |
JP2003062089A (en) | 2001-08-24 | 2003-03-04 | Sumitomo Bakelite Co Ltd | Connector for medical application |
US7037289B2 (en) * | 2001-09-12 | 2006-05-02 | 3M Innovative Properties Company | Apparatus and methods for dispensing an adhesive tissue sealant |
US6790455B2 (en) | 2001-09-14 | 2004-09-14 | The Research Foundation At State University Of New York | Cell delivery system comprising a fibrous matrix and cells |
US7112587B2 (en) | 2001-09-21 | 2006-09-26 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US20050065281A1 (en) | 2001-11-07 | 2005-03-24 | Mathias Lutolf | Synthetic matrix for controlled cell ingrowth and tissue regeneration |
US7035092B2 (en) * | 2001-11-08 | 2006-04-25 | Apple Computer, Inc. | Computer controlled display device |
US6973349B2 (en) * | 2001-12-05 | 2005-12-06 | Cardiac Pacemakers, Inc. | Method and apparatus for minimizing post-infarct ventricular remodeling |
US7169127B2 (en) * | 2002-02-21 | 2007-01-30 | Boston Scientific Scimed, Inc. | Pressure apron direct injection catheter |
JP4229621B2 (en) | 2002-03-05 | 2009-02-25 | 修 加藤 | Chemical injection catheter |
US20030175410A1 (en) | 2002-03-18 | 2003-09-18 | Campbell Phil G. | Method and apparatus for preparing biomimetic scaffold |
US7008411B1 (en) | 2002-09-30 | 2006-03-07 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for treating vulnerable plaque |
US7438692B2 (en) | 2002-10-18 | 2008-10-21 | Mark Tsonton | Localization mechanism for an MRI compatible biopsy device |
JP2006516548A (en) * | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | Drug delivery from rapidly gelled polymer compositions |
US7393339B2 (en) | 2003-02-21 | 2008-07-01 | C. R. Bard, Inc. | Multi-lumen catheter with separate distal tips |
US7250041B2 (en) | 2003-03-12 | 2007-07-31 | Abbott Cardiovascular Systems Inc. | Retrograde pressure regulated infusion |
US20050015048A1 (en) * | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
ES2440654T3 (en) * | 2003-05-05 | 2014-01-29 | Ben-Gurion University Of The Negev Research And Development Authority | Injectable crosslinked polymeric preparations and uses thereof |
EP1649008A2 (en) * | 2003-07-16 | 2006-04-26 | Boston Scientific Limited | Aligned scaffolds for improved myocardial regeneration |
US7129210B2 (en) | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
EP1660145A2 (en) | 2003-08-13 | 2006-05-31 | Medtronic, Inc. | Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices and methods |
US7998112B2 (en) * | 2003-09-30 | 2011-08-16 | Abbott Cardiovascular Systems Inc. | Deflectable catheter assembly and method of making same |
AU2004305574B2 (en) | 2003-12-10 | 2010-08-26 | Cellular Bioengineering, Inc. | Methods and composition for soft tissue feature reconstruction |
US7273469B1 (en) | 2003-12-31 | 2007-09-25 | Advanced Cardiovascular Systems, Inc. | Modified needle catheter for directional orientation delivery |
US20050186240A1 (en) | 2004-02-23 | 2005-08-25 | Ringeisen Timothy A. | Gel suitable for implantation and delivery system |
NZ550964A (en) | 2004-04-28 | 2011-05-27 | Angiodevice Internat Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
GB0419653D0 (en) | 2004-09-04 | 2004-10-06 | Psimedica Ltd | Needle assembly |
TW200633733A (en) | 2004-12-07 | 2006-10-01 | Gelwell Biotech Corp | Biomaterials for guided tissue regeneration and drug delivery |
US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
JP4762785B2 (en) | 2005-06-02 | 2011-08-31 | 西川ゴム工業株式会社 | Gelatin sponge |
EP1917029B1 (en) | 2005-07-27 | 2013-01-23 | Eli Lilly And Company | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
US7732190B2 (en) * | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US8192760B2 (en) * | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
-
2006
- 2006-07-31 US US11/496,824 patent/US7732190B2/en not_active Expired - Fee Related
-
2007
- 2007-07-19 JP JP2009522776A patent/JP2009545372A/en active Pending
- 2007-07-19 EP EP07810637A patent/EP2068830A2/en not_active Withdrawn
- 2007-07-19 WO PCT/US2007/016433 patent/WO2008016490A2/en active Application Filing
- 2007-07-19 EP EP12155231A patent/EP2455065A1/en not_active Withdrawn
-
2010
- 2010-04-07 US US12/756,092 patent/US8486386B2/en not_active Expired - Fee Related
- 2010-04-07 US US12/756,119 patent/US8486387B2/en not_active Expired - Fee Related
-
2013
- 2013-07-15 US US13/941,759 patent/US20140017200A1/en not_active Abandoned
- 2013-09-09 JP JP2013186628A patent/JP2014001236A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11185677B2 (en) | 2017-06-07 | 2021-11-30 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
US11717670B2 (en) | 2017-06-07 | 2023-08-08 | Shifamed Holdings, LLP | Intravascular fluid movement devices, systems, and methods of use |
US11511103B2 (en) | 2017-11-13 | 2022-11-29 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
US10722631B2 (en) | 2018-02-01 | 2020-07-28 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
US11229784B2 (en) | 2018-02-01 | 2022-01-25 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
US11724089B2 (en) | 2019-09-25 | 2023-08-15 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
Also Published As
Publication number | Publication date |
---|---|
US20100196313A1 (en) | 2010-08-05 |
WO2008016490A2 (en) | 2008-02-07 |
US20100196314A1 (en) | 2010-08-05 |
EP2455065A1 (en) | 2012-05-23 |
US20080025943A1 (en) | 2008-01-31 |
EP2068830A2 (en) | 2009-06-17 |
JP2014001236A (en) | 2014-01-09 |
JP2009545372A (en) | 2009-12-24 |
US7732190B2 (en) | 2010-06-08 |
WO2008016490A3 (en) | 2008-10-30 |
US8486386B2 (en) | 2013-07-16 |
US8486387B2 (en) | 2013-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8486387B2 (en) | Modified two-component gelation systems, methods of use and methods of manufacture | |
US8465773B2 (en) | Methods and compositions for treating tissue using silk proteins | |
US8741326B2 (en) | Modified two-component gelation systems, methods of use and methods of manufacture | |
US9775930B2 (en) | Composition for modifying myocardial infarction expansion | |
US8187621B2 (en) | Methods and compositions for treating post-myocardial infarction damage | |
US8377033B2 (en) | Methods of modifying myocardial infarction expansion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |